查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1731669

高尿酸血症药物市场：未来预测（2025-2030）

Hyperuricemia Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

高尿酸血症治疗市场预计将以 6.31% 的复合年增长率成长，从 2025 年的 31.88 亿美元成长到 2030 年的 43.29 亿美元。

高尿酸血症是一种以体内血清尿酸浓度升高为特征的疾病，一般女性为 6 mg/dL 或更高，男性为 7 mg/dL 或更高。高尿酸血症是由于尿酸生成增加、排泄减少或两者兼而有之所致。血尿酸水平升高会导致痛风、肾结石、肾臟损伤、慢性肾臟病等疾病，并与一系列相关疾病有关，包括心血管疾病、糖尿病、高血压、脂肪肝和干癣。根据美国国家生物技术资讯中心的数据，估计21%的一般人群和25%的住院患者患有无症状性高尿酸血症。

市场趋势：

  • 科技进步促进诊断和治疗

高尿酸血症管理的技术创新透过增强诊断和治疗推动了市场成长。发展包括先进的生物标记识别、基因检测和减少尿酸产生的促尿酸排泄药物。基于奈米粒子的标靶治疗等新型药物传输系统也越来越受欢迎。聚乙二醇重组尿酸酶（pegadricase）与mTOR抑制剂免疫耐受技术（ImmTOR™）的组合等精准医疗研究正在重新定义痛风治疗。研究机构和大学的持续研发努力透过为高尿酸血症及其相关疾病提供创新解决方案继续推动市场扩张。

  • 亚太地区是一个快速成长的市场

预计在预测期内，亚太地区高尿酸血症市场将出现最快的成长，这主要是由于久坐不动的生活方式、肥胖、糖尿病和高血压导致的高尿酸血症盛行率不断上升。印度（盛行率为 44.6%）和中国（根据 2017 年 NHANES 的数据，盛行率为 17.7%）等国家的病例数正在增加。医疗保健服务的改善和意识的提高进一步促进了市场的成长。

  • 北美保持较大的市场占有率

受先进的医疗基础设施、人口老化和久坐不动的生活方式的推动，北美占据高尿酸血症市场的很大份额。美国健康与营养检查调查估计，21%（4,300万）的美国成年人和20.6%的墨西哥人患有高尿酸血症。根据美国国家糖尿病、消化和肾臟疾病研究所的报告，11%的男性和6%的女性曾经患有肾结石，慢性肾臟病在65岁以上的人群中最为常见（34%）。这些因素加上人口老化正在推动该地区的市场成长。

本报告介绍的主要企业包括日本化学製药公司、Astellas製药公司、Astra Zeneca、梯瓦製药工业有限公司、默克公司、赛诺菲公司和辉瑞公司。

本报告的主要优点

  • 深刻分析：获得涵盖主要地区和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透。
  • 市场驱动因素和未来趋势：探索动态因素和关键市场趋势以及它们将如何影响市场的未来发展。
  • 可行的建议：利用洞察力进行策略决策，在动态环境中开闢新的业务流和收益。
  • 适用范围广：对于新兴企业、研究机构、顾问公司、中小企业和大型企业来说，它都是实用且具有成本效益的。

它有什么用途？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

分析范围

  • 历史资料（2022-2024）和预测资料（2025-2030）
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按部门和地区（国家）分類的收益成长和预测分析
  • 公司概况（策略、产品、财务资讯、主要趋势等）

目录

第一章 引言

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章 分析方法

  • 分析设计
  • 分析过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章 高尿酸血症药物市场（依疾病类型）

  • 介绍
  • 痛风
  • 慢性肾臟病
  • 其他的

第六章 高尿酸血症药物市场（依治疗方法）

  • 介绍
  • 尿酸排泄促进剂
  • 黄嘌呤氧化酶抑制剂
  • 重组尿酸酶
  • 非药物干预
  • 其他的

第七章 高尿酸血症药物市场（依最终使用者）

  • 介绍
  • 医院
  • 诊所
  • 其他的

第八章 高尿酸血症药物市场（按地区）

  • 介绍
  • 北美洲
    • 依疾病类型
    • 治疗方法
    • 按最终用户
    • 按国家
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 依疾病类型
    • 治疗方法
    • 按最终用户
    • 按国家
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 依疾病类型
    • 治疗方法
    • 按最终用户
    • 按国家
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 依疾病类型
    • 治疗方法
    • 按最终用户
    • 按国家
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 依疾病类型
    • 治疗方法
    • 按最终用户
    • 按国家
      • 中国
      • 日本
      • 韩国
      • 澳洲
      • 印度
      • 印尼
      • 泰国
      • 其他的

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 企业合併、协议、商业合作
  • 竞争仪錶板

第十章 公司简介

  • Nippon Chemiphar
  • Astellas Pharma
  • AstraZeneca
  • Tonghua Dongbao Pharmaceutical
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co.
  • Sanofi SA
  • Pfizer Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • GlaxoSmithKline plc
  • Kissei Pharmaceutical Co., Ltd.
简介目录
Product Code: KSI061617342

The Hyperuricemia Treatment Market is expected to grow at a CAGR of 6.31%, reaching a market size of US$4.329 billion in 2030 from US$3.188 billion in 2025

Hyperuricemia is a condition characterised by elevated levels of serum uric acid in the body, generally greater than 6 mg/dL in women and 7 mg/dL in men. It results from increased uric acid production, decreased excretion or a combination of both factors. This increase in the level of uric acid in the blood leads to disorders like gout, kidney stones, renal disorders, and chronic kidney diseases and is linked to many other related diseases like cardiovascular diseases, diabetes, hypertension, fatty liver disease, Psoriasis and some others. As per the data from the National Center for Biotechnology Information, up to 21% of the general population and 25% of hospitalized patients are estimated to have asymptomatic hyperuricemia.

Market Trends:

  • Technological Advancements Propel Diagnosis and Treatment

Innovations in hyperuricemia management are accelerating market growth through enhanced diagnostics and therapies. Developments include advanced biomarker identification, genetic testing, and uricosuric drugs that reduce uric acid production. Novel drug delivery systems, such as nanoparticle-based targeted therapies, are also gaining traction. Research into precision treatments, like the combination of pegylated recombinant uricase (pegadricase) and immune tolerance technology for mTOR inhibitors (ImmTOR(TM)), is redefining gout therapy. Ongoing R&D efforts by institutions and universities continue to drive market expansion by offering innovative solutions for hyperuricemia and associated conditions.

  • Asia Pacific to Experience Rapid Market Growth

The Asia Pacific region is projected to be the fastest-growing hyperuricemia market during the forecast period, driven by increasing prevalence due to sedentary lifestyles, obesity, diabetes, and hypertension. Countries like India (44.6% prevalence) and China (17.7% in 2017, per NHANES) are seeing rising cases. Improved healthcare access and growing awareness further contribute to market growth.

  • North America Maintains Significant Market Share

North America holds a substantial share of the hyperuricemia market, supported by advanced healthcare infrastructure, an aging population, and sedentary lifestyles. The U.S. National Health and Nutrition Examination Survey estimates 21% of U.S. adults (43 million) and 20.6% of Mexicans have hyperuricemia. The National Institute of Diabetes and Digestive and Kidney Diseases reports that 11% of men and 6% of women experience kidney stones, with chronic kidney disease most prevalent among those aged 65+ (34%). These factors, combined with the aging demographic, drive market growth in the region.

Some of the major players covered in this report include Nippon Chemiphar, Astellas Pharma, AstraZeneca, Tonghua Dongbao Pharmaceutical, Teva Pharmaceutical Industries Ltd., Merck & Co., Sanofi SA, Pfizer Inc., among others.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Hyperuricemia Treatment Market is analysed into the following segments:

By Type of Disease

  • Gout
  • Chronic Kidney Diseases
  • Others

By Treatment Method

  • Uricosuric agents
  • Xanthine Oxidase Inhibitors
  • Recombinant Uricases
  • Non-Pharmacological Interventions
  • Others

By End-User

  • Hospitals
  • Clinics
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. HYPERURICEMIA TREATMENT MARKET BY TYPE OF DISEASE

  • 5.1. Introduction
  • 5.2. Gout
  • 5.3. Chronic Kidney Diseases
  • 5.4. Others

6. HYPERURICEMIA TREATMENT MARKET BY TREATMENT METHOD

  • 6.1. Introduction
  • 6.2. Uricosuric agents
  • 6.3. Xanthine Oxidase Inhibitors
  • 6.4. Recombinant Uricases
  • 6.5. Non-Pharmacological Interventions
  • 6.6. Others

7. HYPERURICEMIA TREATMENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Others

8. HYPERURICEMIA TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type of Disease
    • 8.2.2. By Treatment Method
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Type of Disease
    • 8.3.2. By Treatment Method
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Type of Disease
    • 8.4.2. By Treatment Method
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Type of Disease
    • 8.5.2. By Treatment Method
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Type of Disease
    • 8.6.2. By Treatment Method
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. Australia
      • 8.6.4.5. India
      • 8.6.4.6. Indonesia
      • 8.6.4.7. Thailand
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Nippon Chemiphar
  • 10.2. Astellas Pharma
  • 10.3. AstraZeneca
  • 10.4. Tonghua Dongbao Pharmaceutical
  • 10.5. Teva Pharmaceutical Industries Ltd.
  • 10.6. Merck & Co.
  • 10.7. Sanofi SA
  • 10.8. Pfizer Inc.
  • 10.9. Amgen Inc.
  • 10.10. Takeda Pharmaceutical Company Limited
  • 10.11. Novartis AG
  • 10.12. GlaxoSmithKline plc
  • 10.13. Kissei Pharmaceutical Co., Ltd.